<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cannabinoid hyperemesis syndrome
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cannabinoid hyperemesis syndrome
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cannabinoid hyperemesis syndrome
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jennie A Buchanan, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            George Sam Wang, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Evan Schwarz, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Ganetsky, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H103091275">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannabinoid hyperemesis syndrome (CHS), first described in 2004, causes episodic vomiting and abdominal pain associated with prolonged, high-dose (nearly daily) cannabis use and resolves with cannabis cessation [
         <a href="#rid1">
          1
         </a>
         ]. Symptoms are typically relieved by hot showers or baths. CHS is typically more common in male older adolescents and adults.
        </p>
        <p>
         This topic discusses the epidemiology, evaluation, and management of cannabis hyperemesis syndrome. The following related content is discussed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Clinical manifestations and management of cannabinoid and synthetic cannabinoid intoxication (see
         <a class="medical medical_review" href="/z/d/html/97099.html" rel="external">
          "Cannabis (marijuana): Acute intoxication"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/97100.html" rel="external">
          "Synthetic cannabinoids: Acute intoxication"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cannabis use and cannabis use disorder (see
         <a class="medical medical_review" href="/z/d/html/7797.html" rel="external">
          "Cannabis use and disorder: Epidemiology, pharmacology, comorbidities, and adverse effects"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cannabis withdrawal (see
         <a class="medical medical_review" href="/z/d/html/114326.html" rel="external">
          "Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medical use of cannabis and cannabinoids (see
         <a class="medical medical_review" href="/z/d/html/126970.html" rel="external">
          "Medical use of cannabis and cannabinoids in adults"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2281824146">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall prevalence of cannabinoid hyperemesis syndrome (CHS) is unknown due to lack of definitive criteria or diagnostic tests and occurring in a population that may not disclose substance use. In a study conducted in 2015 in a United States urban emergency department, one-third of patients with near-daily cannabis use met criteria for having had CHS in the prior six months [
         <a href="#rid2">
          2
         </a>
         ]. The authors extrapolated their data to the general United States population and estimated that 2.75 million United States individuals may suffer annually from CHS.
        </p>
        <p>
         Increased rates of CHS have been associated with the legalization and commercialization of cannabis, likely from increased use, higher tetrahydrocannabinol (THC) concentrations in cannabis products, and increased recognition of the syndrome. Since recreational cannabis legalization in Colorado, emergency department visits for cyclic vomiting and health care encounters for vomiting-related disorders have increased [
         <a href="#rid3">
          3,4
         </a>
         ]. In the United States between 2005 and 2014, hospitalizations for cyclical vomiting syndromes (CVS) increased by 60 percent, and concurrent cannabis use in those hospitalized patients increased from 2 to 21 percent [
         <a href="#rid5">
          5
         </a>
         ]. There was a 13-fold increase in emergency department visits for CHS in Canada over the seven years following commercialization of cannabis [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2862692703">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of cannabinoid hyperemesis syndrome (CHS) remains unknown but may be multifactorial, involving cannabinoid metabolism, exposure dose and tolerance resulting in changes in receptor regulation, complex pharmacodynamics at the cannabinoid type 1 (CB1) receptor and other receptors both centrally and peripherally, genetics, and cannabinoid variation in plants [
         <a href="#rid7">
          7-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4154228911">
         <span class="h2">
          Regular and prolonged cannabis use
         </span>
         <span class="headingEndMark">
          —
         </span>
         CHS typically develops in patients with prolonged, daily cannabis use [
         <a href="#rid7">
          7,16,17
         </a>
         ]. However, many individuals use cannabis daily; it is unclear why some develop CHS and others do not.
        </p>
        <p>
         Even though CHS can occur after acute or acute-on-chronic use, most individual with CHS have reported regular cannabis use for over one year and many over at least two years [
         <a href="#rid7">
          7,16,18
         </a>
         ]. Almost all patients with CHS report at least weekly cannabis use, and most report daily cannabis use (eg, three to five times per day) [
         <a href="#rid17">
          17-19
         </a>
         ].
        </p>
        <p>
         Early age of onset of cannabis use may also predispose patients to CHS. One review found that the median age of symptom onset was 24 years [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The route of cannabis use may also play a role. Medical visits for inhaled cannabis are more likely to be associated with CHS while visits involving edibles are more likely for acute psychiatric reactions [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2322688287">
         <span class="h2">
          Role of cannabinoid and TRPV1 receptors
         </span>
         <span class="headingEndMark">
          —
         </span>
         CHS is an apparently paradoxical effect since cannabis and cannabinoid receptor agonists are known antiemetics.
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          Nabilone
         </a>
         and
         <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">
          dronabinol
         </a>
         are synthetic analogs of delta-9-tetrahydrocannabinol (THC) that have been approved by the US Food and Drug Administration (FDA) for treatment of nausea and vomiting associated with cancer chemotherapy [
         <a href="#rid21">
          21-23
         </a>
         ]. CB1 receptors are involved in gastric secretion, sensation, motility, and inflammation. Stimulation of CB1 receptors by endogenous cannabinoids inhibits the hypothalamic-pituitary-adrenal axis and sympathomimetic nervous system response to stress. THC activates the CB1 receptors, non-competitively inhibits emetogenic serotonin receptors, inhibits release of serotonin via presynaptic CB1 receptors, and inhibits gastric function and proemetic dopamine activity via activation of CB1 receptors in the medulla.
        </p>
        <p>
         Chronic cannabis use may be associated with downregulation, desensitization, or internalization of the CB1 receptor [
         <a href="#rid24">
          24
         </a>
         ]. Following cessation of prolonged cannabis use, time is required for regeneration of CB1 receptors and the associated antiemetic effects. This may explain observed persistence of symptoms and gradual recovery phase in patients with CHS.
        </p>
        <p>
         THC is also an agonist at the transient receptor potential cation channel subfamily V member 1 (TRPV1), also known as the
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         receptor or vanilloid receptor. TRPV1 is found in descending pain pathways that regulate antinociception and in ascending pain pathways that mediate nociception [
         <a href="#rid25">
          25
         </a>
         ]. Central nervous system TRPV1 agonism by cannabinoids has potent antiemetic effects by depleting substance P [
         <a href="#rid25">
          25-28
         </a>
         ]. However, overstimulation of TRPV1 from chronic cannabis use may downregulate TRPV1 and contribute to causing abdominal pain, nausea, and emesis. Additional interactions may exist between cannabinoid and TRPV1 receptors that play a role in anxiolysis and inflammation and may also contribute to CHS [
         <a href="#rid29">
          29
         </a>
         ]. A genetic predisposition to CHS may exist that involves TRPV1; one small study found that patients with CHS were more likely to have mutations of TRPV1 [
         <a href="#rid30">
          30
         </a>
         ]. Capsaicin is a potent agonist of TRPV1 and has been studied as a treatment for CHS. (See
         <a class="local">
          'Persistent symptoms: Capsaicin, other antiemetics'
         </a>
         below.)
        </p>
        <p>
         THC-induced splanchnic vasodilation and cutaneous vasoconstriction ("cutaneous stealing syndrome") may be responsible for the abdominal discomfort [
         <a href="#rid31">
          31
         </a>
         ]. Applying persistent heat to the skin (eg, hot showers) may reverse this syndrome and mediate an antiemetic effect by activating peripheral TRPV1, thus inducing peripheral vasodilation, redistributing blood away from the gastrointestinal tract, and mediating the complex gut-brain signaling responsible for emetic effects [
         <a href="#rid25">
          25,32,33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3315507432">
         <span class="h2">
          Cannabinoid metabolism and accumulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannabinoid adipose accumulation and metabolism may contribute to CHS. Cannabinoids are lipophilic and accumulate in central and peripheral adipose tissue. Release of stored cannabinoids from fasting and lipolysis and degradation into pro-emetic agents may precipitate hyperemesis. Genetic differences in the cytochrome P450 system may be associated with accumulation of cannabinoid metabolites in predisposed individuals [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         In a longitudinal study of patients with CHS, whole blood THC concentrations were similar during symptomatic and asymptomatic time periods [
         <a href="#rid19">
          19
         </a>
         ]. However, concentrations of THC metabolites (11-hydroxy-delta-9-THC, 11-nor-9 carboxy-delta-9-THC) were higher during the asymptomatic time period, suggesting that redistribution or metabolism has a greater contribution to acute symptoms compared with simply THC concentrations. Further studies are needed to fully understand the contribution of cannabinoid metabolism and concentrations on the development of CHS.
        </p>
        <p class="headingAnchor" id="H2835024581">
         <span class="h2">
          Cannabis composition (increased THC concentrations)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Increased THC dose exposure may paradoxically be emetogenic and contribute to risk of developing CHS. Even though THC has antiemetic properties, FDA-approved medications (eg,
         <a class="drug drug_general" data-topicid="9995" href="/z/d/drug information/9995.html" rel="external">
          nabilone
         </a>
         ,
         <a class="drug drug_general" data-topicid="9394" href="/z/d/drug information/9394.html" rel="external">
          dronabinol
         </a>
         ) provide a relatively small daily THC dose of 1 to 6 mg [
         <a href="#rid21">
          21-23
         </a>
         ]. Increased THC concentrations in cannabis products, reduction in cannabidiol (CBD) since the 1990s, and increased cannabis use and availability following legalization coincides with the increased incidence of CHS [
         <a href="#rid34">
          34,35
         </a>
         ]. In the United States, the average THC concentration in cannabis strains has been gradually increasing for decades, from approximately 4 percent in 1996 to 17 percent in 2017 [
         <a href="#rid34">
          34,36
         </a>
         ]. In states with legal dispensaries, the THC concentration in most herbal cannabis products was between 15 to 20 percent; some states had mean concentrations &gt;20 percent [
         <a href="#rid35">
          35,37,38
         </a>
         ]. European countries have seen a similar trend [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p>
         Besides THC, the cannabis plant has &gt;400 chemicals, some of which may be emetogenic [
         <a href="#rid39">
          39
         </a>
         ]. CHS has been associated with delta-8-THC use as well as other cannabinoids that are structurally similar to THC [
         <a href="#rid19">
          19,40
         </a>
         ]. CHS has also been reported with synthetic cannabinoid use [
         <a href="#rid41">
          41,42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2134506547">
         <span class="h2">
          Association with cyclical vomiting syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is some clinical overlap between cyclical vomiting syndrome (CVS) and CHS, such as repetitive hot-water bathing behavior. Many adults with CVS self-medicate with cannabis to alleviate nausea [
         <a href="#rid43">
          43
         </a>
         ]. Patients with classic CVS symptoms and modest, intermittent therapeutic use of cannabis are frequently mislabeled as having CHS. However, some patients with CVS-like symptoms who have a history of chronic, frequent cannabis use may actually have CHS; a trial of prolonged abstinence from cannabis can help differentiate these entities. (See
         <a class="medical medical_review" href="/z/d/html/2588.html" rel="external">
          "Cyclic vomiting syndrome", section on 'Chronic cannabis use'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3112226443">
         <span class="h2">
          Other associated factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         CHS has a male predominance, which may reflect a higher prevalence of cannabis use in males [
         <a href="#rid17">
          17,18
         </a>
         ]. Mental health comorbidities, including high rates of depression and anxiety, are reported in a majority of patients with CHS [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2275589398">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H364098835">
         <span class="h2">
          Cyclical pattern
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannabinoid hyperemesis syndrome (CHS) causes abdominal pain, vomiting, and nausea that occurs in a cyclical pattern [
         <a href="#rid17">
          17
         </a>
         ]. Patients are asymptomatic between acute episodes. Patients typically have two or more acute episodes over a six-month period.
        </p>
        <p>
         Symptoms typically start within 24 hours of last cannabis use, which helps differentiate CHS from cannabis withdrawal (symptoms start &gt;24 hours after use). Symptoms can occur day or night, and the onset of symptoms is random as compared with cyclical vomiting syndrome (CVS), which typically is associated with morning onset of symptoms [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2588.html" rel="external">
          "Cyclic vomiting syndrome", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         Acute episodes are associated with a recovery phase with gradual symptom resolution of nausea and vomiting. Acute symptoms typically resolve after cessation of cannabis use, usually after several days. However, symptoms do not always rapidly improve; in one study, several patients still had symptoms two days to two weeks after not using cannabis [
         <a href="#rid17">
          17
         </a>
         ]. In another study, patients had some symptoms for 7 of the 14 days immediately following an emergency department visit for CHS, but most had returned to prior patterns of cannabis use during this time [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3522795844">
         <span class="h2">
          Vomiting and abdominal pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients complain of severe nausea and vomiting, and most complain of abdominal pain. The emesis can be severe with up to 30 episodes daily. The pain is intense and most often diffuse, periumbilical, or epigastric [
         <a href="#rid17">
          17
         </a>
         ]. Patients may be pale and diaphoretic from the pain. The intense nature of the pain also helps differentiate CHS from cannabis withdrawal.
        </p>
        <p>
         Most patients describe normal bowel habits, but some will report diarrhea [
         <a href="#rid17">
          17,45
         </a>
         ]. Some patients also report chills.
        </p>
        <p class="headingAnchor" id="H2968297517">
         <span class="h2">
          Hot-water bathing behavior
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients report that hot showers and/or baths relieve symptoms [
         <a href="#rid19">
          19
         </a>
         ]. This can lead to compulsive bathing behavior with patients sometimes taking multiple showers daily. However, not every study has found this behavior in the majority of patients [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1160974465">
         <span class="h1">
          DIAGNOSTIC EVALUATION
         </span>
        </p>
        <p class="headingAnchor" id="H1896921759">
         <span class="h2">
          Clinical diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cannabinoid hyperemesis syndrome (CHS)
         <strong>
         </strong>
         is a clinical diagnosis. It is usually suspected in a patient with regular cannabis use (at least weekly, typically daily) and recurrent episodes of abdominal pain and vomiting, especially with hot-water bathing behavior. Diagnostic criteria (see
         <a class="local">
          'Diagnostic criteria'
         </a>
         below) can be helpful, but none are definitive. CHS is diagnosed by the resolution of symptoms upon cannabis use cessation, but other serious etiologies should be excluded, either by history (eg, prior negative evaluation for similar pain), examination, or appropriate testing.
        </p>
        <p class="headingAnchor" id="H1441878025">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The evaluation of a patient suspected of having CHS is focused on excluding other etiologies for the symptoms (eg, bowel obstruction) and/or potential complications of excessive vomiting (eg, electrolyte disturbance, acute kidney injury, Boerhaave syndrome). (See
         <a class="medical medical_review" href="/z/d/html/290.html" rel="external">
          "Evaluation of the adult with nontraumatic abdominal or flank pain in the emergency department"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting"
         </a>
         .)
        </p>
        <p>
         Since CHS involves cyclical episodes of abdominal pain, a patient who presents to care for the first time should have a thorough evaluation, even if manifestations are characteristic for CHS. This will typically include abdominal imaging since CHS can cause severe, dramatic pain. In a patient who has had multiple prior presentations with similar symptoms, a previous appropriate evaluation without an acute etiology identified, and a nonperitoneal abdominal examination, testing can be more focused and may not include imaging.
        </p>
        <p>
         The following are reasonable tests to obtain during a visit for an acute exacerbation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete blood count with differential
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum electrolytes, blood urea nitrogen, and creatinine
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum lipase and liver enzymes
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urinalysis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine pregnancy test in a female of childbearing age
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Urine tetrahydrocannabinol (THC) metabolite immunoassay (ie, drug screen); a negative result may be helpful since it likely excludes CHS (unless the patient is only using synthetic cannabinoids, which do not cross-react with the standard urine THC immunoassay)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Radiographic imaging if concern for esophageal or bowel perforation, cholecystitis, or bowel obstruction; choice of imaging depends upon specific concern and may include plain radiographs (eg, posteroanterior and lateral chest, supine and upright abdomen), abdominal ultrasound, or abdominal computed tomography (CT) scan
        </p>
        <p>
        </p>
        <p>
         One study found that 76 percent of patients with CHS have leukocytosis and 58 percent have hypokalemia (although typically mild) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3072534301">
         <span class="h2">
          Diagnostic criteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple criteria have been proposed to assist in diagnosing CHS. The Rome IV criteria is used most commonly [
         <a href="#rid18">
          18
         </a>
         ]. A patient meets the Rome IV criteria if all of the following are present for the last three months with symptom onset at least six months prior to diagnosis:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stereotypical episodic vomiting resembling cyclic vomiting syndrome (CVS) in terms of onset, duration, and frequency (see
         <a class="medical medical_review" href="/z/d/html/2588.html" rel="external">
          "Cyclic vomiting syndrome", section on 'Clinical manifestations'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presentation after prolonged use of cannabis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relief of vomiting episodes by sustained cessation of cannabis use
        </p>
        <p>
        </p>
        <p>
         The criteria also add that CHS may be associated with pathologic bathing behavior (ie, prolonged hot baths or showers), but this is not necessary to meet the criteria.
        </p>
        <p>
         A subsequent proposed modification to these criteria would require at least three episodes per year, cannabis use for greater than one year before symptom onset and average use greater than four times per week, and resolution after cessation of cannabis use for at least six months or at least equal to a duration that spans three typical cycles in the patient [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Simonetto and colleagues proposed similar features to diagnosis CHS, including long-term and weekly cannabis use, cycling vomiting and nausea, resolution with cessation, relief of symptoms with hot bathing, and abdominal pain [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1859234669">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Many disorders can produce nausea with or without vomiting  (
         <a class="graphic graphic_table graphicRef78422" href="/z/d/graphic/78422.html" rel="external">
          table 1
         </a>
         ). Since individuals often self-medicate with cannabis to treat nausea and vomiting, it can be difficult to distinguish between cannabinoid hyperemesis syndrome (CHS) and a primary gastrointestinal disorder. In an adolescent or adult with recurrent episodes of vomiting and abdominal pain, the differential diagnosis is broad and include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cyclical vomiting syndrome (CVS) and CHS are often difficult to differentiate. Both CHS and CVS are associated with recurring episodes of vomiting and repetitive hot-water bathing behavior. Many patients with CVS self-medicate with cannabis to alleviate their daily nausea and can be mislabeled as having CHS if they have only modest, intermittent cannabis use. CHS is the likely cause if symptoms resolve with a trial of prolonged cannabis abstinence. (See
         <a class="medical medical_review" href="/z/d/html/2588.html" rel="external">
          "Cyclic vomiting syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cannabis/cannabinoid withdrawal can also cause abdominal pain, but symptoms typically take more than 24 hours to peak in intensity, the pain is less severe, and there are associated neuropsychiatric symptoms (sleep difficulty, irritability, anger, anxiety, headache, depressed mood). (See
         <a class="medical medical_review" href="/z/d/html/114326.html" rel="external">
          "Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Recurrent intermittent small bowel obstructions can occur from adhesions or an internal hernia. During an episode, imaging would be expected to show the small bowel obstruction. (See
         <a class="medical medical_review" href="/z/d/html/8037.html" rel="external">
          "Etiologies, clinical manifestations, and diagnosis of mechanical small bowel obstruction in adults", section on 'Recurrent intermittent obstruction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic mesenteric ischemia can cause recurrent episodes of dull, crampy, post-prandial abdominal pain (ie, intestinal angina) that subsides over several hours. Patients are typically over 60 years of age and are more likely to be female rather than male. (See
         <a class="medical medical_review" href="/z/d/html/2563.html" rel="external">
          "Chronic mesenteric ischemia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Crohn disease with proximal (ie, gastroduodenal) involvement may present with upper abdominal pain, nausea, and/or postprandial vomiting. Cross-sectional imaging (computed tomography [CT], magnetic resonance imaging [MRI]) and/or upper endoscopy would be expected to show findings consistent with inflammatory bowel disease (eg, gastric/small bowel inflammation, ulceration). (See
         <a class="medical medical_review" href="/z/d/html/4070.html" rel="external">
          "Clinical manifestations, diagnosis, and prognosis of Crohn disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Superior mesenteric artery (SMA) syndrome can present with intermittent symptoms consistent with proximal small bowel obstruction. Patients with SMA syndrome typically have had significant weight loss (or insufficient weight gain in adolescents) leading up to onset of symptoms, and they improve when lying prone, in the left lateral decubitus, or in a knee-chest position. (See
         <a class="medical medical_review" href="/z/d/html/8179.html" rel="external">
          "Superior mesenteric artery syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irritable bowel syndrome can cause cramping abdominal pain with periodic exacerbations. Patients tend to have alteration in bowel habits (ie, constipation and/or diarrhea) and are less likely to vomit. (See
         <a class="medical medical_review" href="/z/d/html/2630.html" rel="external">
          "Clinical manifestations and diagnosis of irritable bowel syndrome in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cholelithiasis can cause intermittent episodes of upper abdominal pain and vomiting (ie, biliary colic), typically following consumption of a fatty meal. An abdominal ultrasound is the most sensitive modality for detecting cholelithiasis. (See
         <a class="medical medical_review" href="/z/d/html/654.html" rel="external">
          "Overview of gallstone disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical celiac disease may present without diarrhea. Celiac disease can be differentiated by serologic evaluation and small bowel biopsy. (See
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults", section on 'Atypical celiac disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4771.html" rel="external">
          "Diagnosis of celiac disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nausea and vomiting of pregnancy, gastroparesis, gastroesophageal reflux, gastric outlet obstruction, eosinophilic gastroenteritis, chronic idiopathic intestinal pseudo-obstruction, rumination syndrome, and functional nausea and vomiting disorders are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2537.html" rel="external">
          "Approach to the adult with nausea and vomiting", section on 'Chronic disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute intermittent porphyria causes frequent, recurrent attacks that typically include abdominal pain, vomiting, and sensory and motor neuropathy. Urinary porphyrin precursors and porphyrins are elevated during attacks. (See
         <a class="medical medical_review" href="/z/d/html/7096.html" rel="external">
          "Acute intermittent porphyria: Pathogenesis, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3393441276">
         <span class="h1">
          MANAGEMENT
         </span>
        </p>
        <p class="headingAnchor" id="H3138895630">
         <span class="h2">
          Acute episode
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acute treatment consists of symptomatic care including intravenous (IV) fluid hydration and antiemetic therapy [
         <a href="#rid48">
          48,49
         </a>
         ]. A standard antiemetic (eg,
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ,
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         ) is often initially administered but is typically ineffective. We discourage administering opioids given the risk of long-term adverse effects (eg, tolerance, dependence, opioid-induced hyperalgesia, opioid use disorder, and overdose), especially in patients with recurrent presentations for pain. (See
         <a class="medical medical_review" href="/z/d/html/120966.html" rel="external">
          "Risk of long term opioid use and misuse after prescription of opioids for pain"
         </a>
         .)
        </p>
        <p>
         In a patient with abdominal pain and vomiting presumed to be from cannabinoid hyperemesis syndrome (CHS), our approach is as follows:
        </p>
        <p class="headingAnchor" id="H3374480888">
         <span class="h3">
          All patients: IV fluids, dopamine antagonists
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Provide fluid repletion (eg, 1 L of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or buffered crystalloid solution such as
         <a class="drug drug_general" data-topicid="108196" href="/z/d/drug information/108196.html" rel="external">
          lactated Ringer
         </a>
         over one hour).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We suggest administering
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         (observational studies have used 0.625 or 1.25 mg) or
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         (0.05 to 0.1 mg/kg, maximum single dose 2.5 mg). Both of these medications have been found to be effective in controlling acute symptoms of CHS.
        </p>
        <p>
        </p>
        <p>
         Evidence for the use of dopamine antagonists for CHS includes a trial, observational study, and case reports [
         <a href="#rid50">
          50
         </a>
         ]. A trial of 33 adults with cannabis use and active emesis compared
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         0.05 mg/kg, haloperidol 0.1 mg/kg, or
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         8 mg as a first approach [
         <a href="#rid51">
          51
         </a>
         ]. Two hours following drug administration, haloperidol more effectively improved self-rated abdominal pain and nausea compared with ondansetron (10-point visual analog scale score decrease 4.6 versus 2.3 cm, difference 2.3 cm, 95% CI 0.6-4.0 cm). Efficacy was similar between haloperidol doses, but two patients who received the higher dose had return visits for acute dystonia. Patients who received haloperidol were discharged from the emergency department faster after receiving study drug (3.1 versus 5.6 hours, difference 2.5 hours, 95% CI 0.1-5.0 hours). Haloperidol was associated with higher treatment success (54 versus 29 percent), but this finding was not statistically significant. Despite low enrollment, lower crossover rate than expected (precluding paired sample analysis), and the trial being halted early for efficacy, the results were significant with a stronger-than-anticipated effect size.
        </p>
        <p>
         An observational study and case reports have also documented the successful use of dopamine antagonists such as
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         to abort severe episodes of hyperemesis [
         <a href="#rid7">
          7,52-54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1107928264">
         <span class="h3">
          Persistent symptoms: Capsaicin, other antiemetics
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a patient with persistent symptoms despite IV fluids and dopamine antagonist, we suggest topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         cream. We apply a cream with a concentration of 0.025 to 0.1% in a thin film over the abdomen. In our experience, it appears to be effective in treatment after initial application. It has minimal adverse effects, but some patients tend not to tolerate subsequent applications due to the skin discomfort of capsaicin. If it is effective and tolerable for a patient, capsaicin has the advantage that it can be continued at home since some symptoms can persist even with abstinence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer an antiemetic with a different pharmacologic activity than the original antiemetic, if given. Options include
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         ,
         <a class="drug drug_general" data-topicid="9642" href="/z/d/drug information/9642.html" rel="external">
          metoclopramide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9816" href="/z/d/drug information/9816.html" rel="external">
          prochlorperazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">
          diphenhydramine
         </a>
         , although these are often ineffective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A benzodiazepine (eg,
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         1 mg IV) can be used as an antiemetic adjunct [
         <a href="#rid55">
          55
         </a>
         ]. Benzodiazepines should be administered with caution given risk for dependence. These should not be used as first-line agents but rather as second- or third-line agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a patient refractory to all other treatments,
         <a class="drug drug_general" data-topicid="9305" href="/z/d/drug information/9305.html" rel="external">
          aprepitant
         </a>
         can be administered, but evidence is limited to one case report [
         <a href="#rid56">
          56
         </a>
         ]. Aprepitant inhibits the substance P/neurokinin 1 (NK
         <sub>
          1
         </sub>
         ) receptor, which is similar to the postulated mechanism of action of
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         cream.
        </p>
        <p>
        </p>
        <p>
         Evidence for the use of
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         for CHS includes a trial and many observational studies. A trial of 30 patients with CHS treated with capsaicin cream 0.1% (5 grams applied to abdomen) or placebo (moisturizing cream) found capsaicin was associated with less severe nausea 60 minutes after application (10-point visual analog scale score 3.2 versus 6.4 cm, difference -3.2 cm, 95% CI -0.9 to -5.4 cm) [
         <a href="#rid57">
          57
         </a>
         ]. However, patients randomized to the capsaicin treatment had less severe nausea at baseline, and the difference at 60 minutes did not achieve significance (visual analog scale decrease 2.8 versus 2.1 cm, percent reduction 46 versus 25 percent, difference 21 percent, 95% CI -5.6 to 47.9 percent). More patients treated with capsaicin had complete resolution of nausea (29 versus 0 percent, relative risk 3.4, 95% CI 1.6-7.1) and no further episodes of vomiting after two hours (94 versus 62 percent), but the latter finding was not statistically significant. Only one patient did not tolerate capsaicin due to skin irritation.
        </p>
        <p>
         Systematic reviews, retrospective studies, and case series have found that topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         cream is associated with an improvement in abdominal pain and emesis in patients not responsive to
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         or benzodiazepines [
         <a href="#rid7">
          7,26,50,58-61
         </a>
         ]. It is hypothesized that capsaicin may provide relief by its potent agonism on the transient receptor potential vanilloid 1 (TRPV1). In a retrospective study of 43 patients treated for CHS in the emergency department, use of capsaicin cream decreased total medications administered and reduced opioid requirements; two-thirds of patients required no further treatment prior to discharge [
         <a href="#rid62">
          62
         </a>
         ]. In a separate retrospective study of 201 patients with CHS, capsaicin cream was associated with greater efficacy for symptom relief than other treatments but was not associated with lower rates of admission or return emergency department visits within 24 hours [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4254829082">
         <span class="h2">
          Long-term management
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advise all patients with CHS to forego further cannabis use and offer mental health or substance use treatment referral. A systematic review found that symptoms completely resolved in 97 percent of patients following stopping cannabis use [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         The patient must understand that it may take several weeks of cannabis abstinence for symptoms to resolve and that symptoms may worsen or return if cannabis is resumed. However, it is often difficult for patients to abruptly abstain from cannabis use since CHS often occurs in patients with cannabis use disorder and many will develop a withdrawal syndrome [
         <a href="#rid19">
          19,64
         </a>
         ]. For these patients, the clinician can advise use of products with decreased tetrahydrocannabinol (THC) concentrations and reduced frequency of use with an ultimate goal of abstinence. However, it is unknown if reduction of use (instead of abstinence) prevents CHS recurrence. Management of cannabis withdrawal and cannabis use disorder are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/114326.html" rel="external">
          "Cannabis withdrawal: Epidemiology, clinical features, diagnosis, and treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7796.html" rel="external">
          "Cannabis use disorder: Clinical features, screening, diagnosis, and treatment"
         </a>
         .)
        </p>
        <p>
         For patients with protracted symptoms who present repeatedly to the emergency department with frequent vomiting and retching, it is reasonable to individualize treatment, which may involve earlier or primary use of
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         or
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         to control symptoms. An evaluation to exclude other etiologies of symptoms or complications of repeated vomiting are still appropriate in these patients, especially those whose symptoms are poorly controlled. Home use of
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         cream, if initially effective and tolerable, is another option for patients with persistent symptoms.
        </p>
        <p class="headingAnchor" id="H1692034013">
         <span class="h1">
          ADDITIONAL RESOURCES
         </span>
        </p>
        <p class="headingAnchor" id="H4028657621">
         <span class="h2">
          Regional poison control centers
         </span>
         <span class="headingEndMark">
          —
         </span>
         Regional poison control centers in the United States are available at all times for consultation on patients with known or suspected poisoning, and who may be critically ill, require admission, or have clinical pictures that are unclear (1-800-222-1222). In addition, some hospitals have medical toxicologists available for bedside consultation. Whenever available, these are invaluable resources to help in the diagnosis and management of ingestions or overdoses. Contact information for poison centers around the world is provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/138307.html" rel="external">
          "Society guideline links: Regional poison control centers"
         </a>
         .)
        </p>
        <p>
         The Partnership at Drugfree.org maintains a
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.drugfree.org%2Fdrug-guide%3Fsearch-text%3Dmolly&amp;token=qgu634WFjUKBnks11cLIdSO35J2mOhJsWrWGQFHQWJ8HsdQkm4Z5tSCXw9EinxrVKShgZc0onHiBKQniKdO9TA%3D%3D&amp;TOPIC_ID=141176" target="_blank">
          drug guide
         </a>
         for 40 commonly misused drugs including common slang terms.
        </p>
        <p class="headingAnchor" id="H418829992">
         <span class="h2">
          Society guideline links
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114308.html" rel="external">
          "Society guideline links: Cannabis use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114015.html" rel="external">
          "Society guideline links: Treatment of acute poisoning caused by recreational drug or alcohol use"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3770401135">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/131890.html" rel="external">
          "Patient education: Cannabis hyperemesis syndrome (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3882024951">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
         – Cannabinoid hyperemesis syndrome (CHS) is a syndrome of cyclic abdominal pain, vomiting, or nausea in older adolescents and adults with chronic cannabis use. Relief of symptoms with hot showers or baths is a common feature. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – We perform laboratory and/or imaging studies to exclude other etiologies or to identify complications of excessive vomiting. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – CHS
         <strong>
         </strong>
         is a clinical diagnosis. It is usually suspected in a patient with regular cannabis use and recurrent episodes of severe abdominal pain and vomiting, especially with hot-water bathing behavior. CHS is diagnosed by the resolution of symptoms upon cannabis use cessation, but other serious etiologies should be excluded either by history (eg, prior negative evaluation for similar pain), examination, or appropriate testing. (See
         <a class="local">
          'Diagnostic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The Rome IV diagnostic criteria can assist in diagnosing CHS. All of the following need to be present for the last three months with symptom onset at least six months prior to diagnosis (see
         <a class="local">
          'Diagnostic criteria'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Stereotypical episodic vomiting resembling cyclic vomiting syndrome (CVS) in terms of onset, duration, and frequency
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Presentation after prolonged use of cannabis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Relief of vomiting episodes by sustained cessation of cannabis use
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management of acute episode –
         </strong>
         We provide symptomatic care and intravenous (IV) fluids. In a patient with abdominal pain and/or vomiting presumed from CHS, we suggest administering
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         or
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         instead of other antiemetic agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The droperidol dose is 0.625 or 1.25 mg and the haloperidol dose is 0.05 to 0.1 mg/kg, maximum single dose 2.5 mg. Other antiemetics such as
         <a class="drug drug_general" data-topicid="9719" href="/z/d/drug information/9719.html" rel="external">
          ondansetron
         </a>
         can be used, although they are typically ineffective. (See
         <a class="local">
          'All patients: IV fluids, dopamine antagonists'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a patient with persistent symptoms, we suggest topical
         <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">
          capsaicin
         </a>
         cream (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We apply a cream with a concentration of 0.025 to 0.1% in a thin film over the abdomen. (See
         <a class="local">
          'Persistent symptoms: Capsaicin, other antiemetics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Long-term management
         </strong>
         – We advise all patients with CHS to forego further cannabis use and offer mental health or substance use treatment referral. The patient must understand that it may take several weeks of cannabis abstinence for symptoms to resolve, and only abstinence will prevent recurrence. In a patient who cannot abruptly abstain, we advise use of products with decreased tetrahydrocannabinol (THC) concentrations and reduced frequency of use with an ultimate goal of abstinence. (See
         <a class="local">
          'Long-term management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Allen JH, de Moore GM, Heddle R, Twartz JC. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. Gut 2004; 53:1566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Habboushe J, Rubin A, Liu H, Hoffman RS. The Prevalence of Cannabinoid Hyperemesis Syndrome Among Regular Marijuana Smokers in an Urban Public Hospital. Basic Clin Pharmacol Toxicol 2018; 122:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim HS, Anderson JD, Saghafi O, et al. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med 2015; 22:694.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang GS, Buttorff C, Wilks A, et al. Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado. JAMA Netw Open 2021; 4:e2125063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siddiqui MT, Bilal M, Singh A, et al. Prevalence of cannabis use has significantly increased in patients with cyclic vomiting syndrome. Neurogastroenterol Motil 2020; 32:e13806.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myran DT, Roberts R, Pugliese M, et al. Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada. JAMA Netw Open 2022; 5:e2231937.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. J Med Toxicol 2017; 13:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krowicki ZK, Moerschbaecher JM, Winsauer PJ, et al. Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors. Eur J Pharmacol 1999; 371:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lundberg DJ, Daniel AR, Thayer SA. Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture. Neuropharmacology 2005; 49:1170.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45:405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCallum RW, Soykan I, Sridhar KR, et al. Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study. Aliment Pharmacol Ther 1999; 13:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmani NA, Sim-Selley LJ, Martin BR, et al. Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation. Eur J Pharmacol 2003; 459:83.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharkey KA, Darmani NA, Parker LA. Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol 2014; 722:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shinka T, Agarwal R, Lazarides A, Levey R. Cannabinoid-induced Gastroparesis. Am J Gastroenterol 2011; 106:S189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Sickle MD, Oland LD, Mackie K, et al. Distribution of the cannabinoid 1 receptor in the brainstem and gut: a novel neuroregulatory system in emesis [abstract]. Gastroenterology 2001; 120:A197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perisetti A, Gajendran M, Dasari CS, et al. Cannabis hyperemesis syndrome: an update on the pathophysiology and management. Ann Gastroenterol 2020; 33:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rotella JA, Ferretti OG, Raisi E, et al. Cannabinoid hyperemesis syndrome: A 6-year audit of adult presentations to an urban district hospital. Emerg Med Australas 2022; 34:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanghellini V, Chan FK, Hasler WL, et al. Gastroduodenal Disorders. Gastroenterology 2016; 150:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wightman RS, Metrik J, Lin TR, et al. Cannabis Use Patterns and Whole-Blood Cannabinoid Profiles of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome. Ann Emerg Med 2023; 82:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Monte AA, Shelton SK, Mills E, et al. Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study. Ann Intern Med 2019; 170:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Todaro B. Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting. J Natl Compr Canc Netw 2012; 10:487.
          </a>
         </li>
         <li class="breakAll">
          Dronabinol [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018651s029lbl.pdf (Accessed on October 26, 2023).
         </li>
         <li class="breakAll">
          Nabilone [prescribing information]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf (Accessed on October 26, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Villares J. Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain. Neuroscience 2007; 145:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Louis-Gray K, Tupal S, Premkumar LS. TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids. Int J Mol Sci 2022; 23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards JR, Lapoint JM, Burillo-Putze G. Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment. Clin Toxicol (Phila) 2018; 56:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmani NA, Ray AP. Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting. Chem Rev 2009; 109:3158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rudd JA, Nalivaiko E, Matsuki N, et al. The involvement of TRPV1 in emesis and anti-emesis. Temperature (Austin) 2015; 2:258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lowin T, Straub RH. Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis. Arthritis Res Ther 2015; 17:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russo EB, Spooner C, May L, et al. Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation. Cannabis Cannabinoid Res 2022; 7:336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Razban M, Exadaktylos AK, Santa VD, Heymann EP. Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department. Int J Emerg Med 2022; 15:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schicho R, Donnerer J, Liebmann I, Lippe IT. Nociceptive transmitter release in the dorsal spinal cord by capsaicin-sensitive fibers after noxious gastric stimulation. Brain Res 2005; 1039:108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darmani NA, Chebolu S, Zhong W, et al. Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonist Δ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva). Eur J Pharmacol 2014; 722:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandra S, Radwan MM, Majumdar CG, et al. New trends in cannabis potency in USA and Europe during the last decade (2008-2017). Eur Arch Psychiatry Clin Neurosci 2019; 269:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smart R, Caulkins JP, Kilmer B, et al. Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state. Addiction 2017; 112:2167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ElSohly MA, Ross SA, Mehmedic Z, et al. Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997. J Forensic Sci 2000; 45:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cash MC, Cunnane K, Fan C, Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. PLoS One 2020; 15:e0230167.
          </a>
         </li>
         <li class="breakAll">
          Regulated Marijuana: Market Update. University of Colorado Leeds School of Business, MPG Consulting; 2020. https://sbg.colorado.gov/sites/sbg/files/2020-Regulated-Marijuana-Market-Update-Final.pdf (Accessed on October 26, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol 2012; 2:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenthal J, Howell M, Earl V, Malik M. Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use. Am J Med 2021; 134:e582.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ukaigwe A, Karmacharya P, Donato A. A Gut Gone to Pot: A Case of Cannabinoid Hyperemesis Syndrome due to K2, a Synthetic Cannabinoid. Case Rep Emerg Med 2014; 2014:167098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bick BL, Szostek JH, Mangan TF. Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome. Mayo Clin Proc 2014; 89:1168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan T, Hillard CJ, Rein L, et al. Patterns of Cannabis Use in Patients With Cyclic Vomiting Syndrome. Clin Gastroenterol Hepatol 2020; 18:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wightman RS, Metrik J, Lin TR, et al. Cannabinoid hyperemesis syndrome: clinical trajectories and patterns of use three months following a visit to the emergency department. Acad Emerg Med 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ma PH, Joyce KM, Morton T, et al. A focused, longitudinal analysis of cannabinoid hyperemesis syndrome symptomatology. Int J Emerg Med 2021; 14:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkatesan T, Levinthal DJ, Li BUK, et al. Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome. Neurogastroenterol Motil 2019; 31 Suppl 2:e13606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonetto DA, Oxentenko AS, Herman ML, Szostek JH. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc 2012; 87:114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richards JR. Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department. J Emerg Med 2018; 54:354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chocron Y, Zuber JP, Vaucher J. Cannabinoid hyperemesis syndrome. BMJ 2019; 366:l4336.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabbineni M, Scott W, Punia K, et al. Dopamine antagonists and topical capsaicin for cannabis hyperemesis syndrome (CHS) in the emergency department: a systematic review of direct evidence. Acad Emerg Med 2023.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ruberto AJ, Sivilotti MLA, Forrester S, et al. Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial. Ann Emerg Med 2021; 77:613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med 2013; 31:1003.e5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Witsil JC, Mycyk MB. Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome. Am J Ther 2017; 24:e64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee C, Greene SL, Wong A. The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome. Clin Toxicol (Phila) 2019; 57:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kheifets M, Karniel E, Landa D, et al. Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series. Isr Med Assoc J 2019; 21:404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parvataneni S, Varela L, Vemuri-Reddy SM, Maneval ML. Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome. Cureus 2019; 11:e4825.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean DJ, Sabagha N, Rose K, et al. A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome. Acad Emerg Med 2020; 27:1166.
          </a>
         </li>
         <li class="breakAll">
          Lapoint J. Capsaicin cream for treatment of cannabinoid hyperemesis syndrome. American College of Medical Toxicology Annual Scientific Meeting abstracts. Abstract 51. 2014. Available at: http://www.acmt.net/Abstracts_41-60.html#fiftyone (Accessed on August 30, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezieck L, Hafez Z, Conicella A, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. Clin Toxicol (Phila) 2017; 55:908.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graham J, Barberio M, Wang GS. Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents: A Case Series. Pediatrics 2017; 140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pourmand A, Esmailian G, Mazer-Amirshahi M, et al. Topical capsaicin for the treatment of cannabinoid hyperemesis syndrome, a systematic review and meta-analysis. Am J Emerg Med 2021; 43:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner S, Hoppe J, Zuckerman M, et al. Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department. Clin Toxicol (Phila) 2020; 58:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kum V, Bell A, Fang W, VanWert E. Efficacy of topical capsaicin for cannabinoid hyperemesis syndrome in a pediatric and adult emergency department. Am J Emerg Med 2021; 49:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bahji A, Stephenson C, Tyo R, et al. Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis. JAMA Netw Open 2020; 3:e202370.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 141176 Version 1.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15479672" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29327809" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Prevalence of Cannabinoid Hyperemesis Syndrome Among Regular Marijuana Smokers in an Urban Public Hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25903855" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cyclic vomiting presentations following marijuana liberalization in Colorado.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34533572" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Changes in Emergency Department Encounters for Vomiting After Cannabis Legalization in Colorado.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31990435" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prevalence of cannabis use has significantly increased in patients with cyclic vomiting syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36112372" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28000146" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10357256" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Delta9-tetrahydrocannabinol inhibits gastric motility in the rat through cannabinoid CB1 receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16157354" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Delta(9)-Tetrahydrocannabinol-induced desensitization of cannabinoid-mediated inhibition of synaptic transmission between hippocampal neurons in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16678907" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9892882" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: a double-blind, randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12505537" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Antiemetic and motor-depressive actions of CP55,940: cannabinoid CB1 receptor characterization, distribution, and G-protein activation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24184696" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cannabinoid-induced Gastroparesis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Distribution of the cannabinoid 1 receptor in the brainstem and gut: a novel neuroregulatory system in emesis [abstract]
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33162734" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Cannabis hyperemesis syndrome: an update on the pathophysiology and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35199462" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Cannabinoid hyperemesis syndrome: A 6-year audit of adult presentations to an urban district hospital.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27147122" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Gastroduodenal Disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37479395" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Cannabis Use Patterns and Whole-Blood Cannabinoid Profiles of Emergency Department Patients With Suspected Cannabinoid Hyperemesis Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30909297" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Acute Illness Associated With Cannabis Use, by Route of Exposure: An Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491047" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491047" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22491047" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Cannabinoids in the treatment of chemotherapy-induced nausea and vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17222515" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Chronic use of marijuana decreases cannabinoid receptor binding and mRNA expression in the human brain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36077412" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : TRPV1: A Common Denominator Mediating Antinociceptive and Antiemetic Effects of Cannabinoids.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28730896" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Cannabinoid hyperemesis syndrome: potential mechanisms for the benefit of capsaicin and hot water hydrotherapy in treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19522506" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27227028" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The involvement of TRPV1 in emesis and anti-emesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26343051" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34227878" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cannabinoid Hyperemesis Syndrome Survey and Genomic Investigation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36076180" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cannabinoid hyperemesis syndrome and cannabis withdrawal syndrome: a review of the management of cannabis-related syndrome in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15781052" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Nociceptive transmitter release in the dorsal spinal cord by capsaicin-sensitive fibers after noxious gastric stimulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24157976" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Additive antiemetic efficacy of low-doses of the cannabinoid CB(1/2) receptor agonistΔ(9)-THC with ultralow-doses of the vanilloid TRPV1 receptor agonist resiniferatoxin in the least shrew (Cryptotis parva).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30671616" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : New trends in cannabis potency in USA and Europe during the last decade (2008-2017).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28556310" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Variation in cannabis potency and prices in a newly legal market: evidence from 30 million cannabis sales in Washington state.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10641915" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32214334" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Mapping cannabis potency in medical and recreational programs in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32214334" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Mapping cannabis potency in medical and recreational programs in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23983983" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cannabis, a complex plant: different compounds and different effects on individuals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34343506" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Cannabinoid Hyperemesis Syndrome Secondary to Delta-8 THC Use.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24872901" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A Gut Gone to Pot: A Case of Cannabinoid Hyperemesis Syndrome due to K2, a Synthetic Cannabinoid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25092369" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Synthetic cannabinoid leading to cannabinoid hyperemesis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31352091" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Patterns of Cannabis Use in Patients With Cyclic Vomiting Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37387520" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cannabinoid hyperemesis syndrome: clinical trajectories and patterns of use three months following a visit to the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34325648" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A focused, longitudinal analysis of cannabinoid hyperemesis syndrome symptomatology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31241817" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Role of chronic cannabis use: Cyclic vomiting syndrome vs cannabinoid hyperemesis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22305024" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cannabinoid hyperemesis: a case series of 98 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29310960" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Cannabinoid Hyperemesis Syndrome: Pathophysiology and Treatment in the Emergency Department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31324702" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Cannabinoid hyperemesis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37391387" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Dopamine antagonists and topical capsaicin for cannabis hyperemesis syndrome (CHS) in the emergency department: a systematic review of direct evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33160719" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Intravenous Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC): A Randomized, Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23583118" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Haloperidol for treatment of cannabinoid hyperemesis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25393073" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Haloperidol, a Novel Treatment for Cannabinoid Hyperemesis Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30729854" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31280510" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Resolution of Cannabinoid Hyperemesis Syndrome with Benzodiazepines: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31403013" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Emerging Role of Aprepitant in Cannabis Hyperemesis Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32569429" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32569429" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : A Pilot Trial of Topical Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28494183" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29122973" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Capsaicin Cream for Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents: A Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33493995" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Topical capsaicin for the treatment of cannabinoid hyperemesis syndrome, a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31482758" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Efficacy and safety of topical capsaicin for cannabinoid hyperemesis syndrome in the emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34242945" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Efficacy of topical capsaicin for cannabinoid hyperemesis syndrome in a pediatric and adult emergency department.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32271390" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Prevalence of Cannabis Withdrawal Symptoms Among People With Regular or Dependent Use of Cannabinoids: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
